BioNotebook: Sangamo/Biogen, Adamas/Forest, Zymeworks/Lilly, Sunesis
This article was originally published in Scrip
Sangamo gains 38% on Biogen license deal; Adamas collects $40m from Forest; Zymeworks inks deal with Lilly's Imclone, raises $15m; and Sunesis regains assets from Biogen, Millennium.
You may also be interested in...
Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Bioverativ revealed its first transaction since spinning out from Biogen with the acquisition of True North for $400m plus up to $425m in milestone payments. The deal gives Bioverativ a clinical asset, helping to fill the gap between preclinical programs and commercial products in its R&D pipeline.
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.